Cerevel launches phase 3 Parkinson’s disease clinical trials for tavapadon
Parkinson’s disease clinical trials : Cerevel Therapeutics, a US biopharma company, has initiated a phase 3 clinical trial program for evaluating tavapadon in Parkinson’s disease patients, as per the latest clinical trial news. Tavapadon is being developed as an orally-bioavailable, selective partial agonist of the dopamine D1 and D5 receptors, and is being assessed for […]